Research programme: antibodies - AP Biosciences/Tasly Pharmaceutical Group
Latest Information Update: 28 Aug 2023
At a glance
- Originator AP Biosciences; Tasly Pharmaceutical Group
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for research development in Unspecified in China (Parenteral)
- 28 Aug 2023 No recent reports of development identified for research development in Unspecified in Taiwan (Parenteral)